ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

vilagletistat

Also written as “ZED1227 + SIGE”, “TAK-227” and “ZED1227”.

Its studies are mostly in Celiac Disease · Non-alcoholic Fatty Liver Disease, led by 2 companies.

Drug pageZED1227: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Mar 4, 20223 company-led studies, 1 open or runningNext primary completion: Aug 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Dr. Falk Pharma21 open or runningphase 2since Mar 4, 2022Mar 4, 2022Aug 2027phase 2 · NCT07298343
Takedaits history only10 open or runningphase 1since Apr 6, 2023Apr 6, 2023none ahead

Also a collaborator on its studies: Takeda Development Center Americas.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Dr. Falk Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Mar 4, 2022First study: phase 2 study in Non-alcoholic Fatty Liver DiseaseFirst studyNCT05305599 · 186 enrolled · Germany
  2. Feb 13, 2025Named vilagletistatINNProposed as its International Nonproprietary Name in WHO's List 132 · before, TAK-227, ZED1227
  3. Dec 17, 2025Phase 2 study in Celiac DiseaseNCT07298343 · 356 planned · Germany

Ahead

  1. Aug 2027Primary completion: phase 2 study in Celiac DiseaseNCT07298343

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 Dr. Falk Pharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07298343Celiac Disease · Germany2RecruitingAug 2027356
NCT05305599Non-alcoholic Fatty Liver Disease · Germany2CompletedJun 7, 2023186

How it is read

Names in the registry

  • “ZED1227 + SIGE”, 1 entry
  • “TAK-227”, 1 entry
  • “ZED1227”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.